جستجوی مقالات مرتبط با کلیدواژه "مینوکسیدیل" در نشریات گروه "پزشکی"

Androgenetic alopecia (AGA) is the most common form of alopecia in men, worldwide and topical minoxidil appears to be the most effective and safe treatment for AGA beside oral finasteride. Safety assessment of topical minoxidil formulation could be conducted using in vivo studies on human volunteers. Using skin biophysical parameters is a fast and noninvasive method for safety assessment of topical products.
A topical combination of Minoxidil 5% solution in combination with chamomile extract from Iran’s pharmaceutical market tested on the skin of the forearm of 15 healthy volunteers. Changes in transepidermal water loss (TEWL), stratum corneum hydration, pH, melanin and hemoglobin contents have been evaluated, using biometric assessments with MPA 580 Cutometer®.
There was not any significant change in skin hydration (P=0.692), TEWL (P=0.191), stratum corneum pH (P=0.613), melanin (P=0.533), and hemoglobin (P=0.579) contents before and after topical minoxidil application.
No significant change detected in skin erythema and assessed parameters Application of minoxidil 5% chamomile 7% topical solution on human volunteers has not shown any adverse effects and these formulations could be recommended to use.

Considering the prevalence of Alopecia areata,, failure of treatment, and the unknown pathogenesis of this illness, a comparative study was performed by using topical Minoxidil 2% and topical rosemary solution alone and in combination to treatment this disease. This study is a clinical trial performed on 200 patients with Alopecia areata referring to Hamzeh clinic of Fasa during the years 2012 and 2013. They were divided into four groups by random permutation, each group contained 50 patients. Group one received the combination of topical Minoxidil 2% and topical rosemary, group two received only topical Minoxidil 2% solution, group three received only topical rosemary solution and the fourth group, the case-control group, did not receive any medication and were just advised to rub the site of the disease for the same period of time. The patients were under observation for one year. The Results of this investigation showed that the best remissions after treatments were as follow (respectively): combination of topical Minoxidil 2% and topical rosemary (27 patient=54 %), Minoxidil 2% solution (23 patients =46%), rosemary solution (21 patients =42%), and case- control group (9 patients =18%). These results showed that despite better response to the combination of rosemary and Minoxidil solutions in comparison to the two other treated groups, the changes were minimal and statistically insignificant (P-value =0.0411). Using the combination of both rosemary and Minoxidil is more effective than the individual one on treatment of Alopecia areata.

Androgenetic alopecia (AGA) is the most common type of alopecia in men. Currently، minoxidil is the only topical drug which has been approved by FDA for the treatment of AGA. However، its efficacy is restricted because of its low skin penetration. Since vesicular systems such as liposomes and niosomes have higher efficacy and lower adverse effects، this study was conducted to compare the efficacy of topical niosomal minoxidil with conventional minoxidil in the treatment of AGA. This study was a randomized، controlled double-blind clinical trial. Ninety male patients with AGA according to Hamilton criteria were enrolled into this trial. The participants applied the interversion to which they were allocated twice a day، and were evaluated monthly for 6 months by a physician and patients self-assessments. Eighty-eight patients completed the trial. Mean increased hair count in niosomal minoxidil group and conventional minoxidil group in the last visit were 28. 18±11. 00 and 14. 22±5. 23، respectively (P<0. 001). Moreover، evaluation of treatment response according to the patients self-assessments were 8. 72±5. 03 and 3. 33±2. 67 in niosomal and conventional minoxidil، respectively، which revealed more satisfaction in niosomal group (P=0. 001). With the exception of two cases in niosomal minoxidil group whom were withdraw due to scalp itching and erthema no other adverse effect was observed in either group. In the present study، application of topical niosomal minoxidil revealed an increase in the hair count in comparison with conventional minoxidil solution. Application of this new formulation for the treatment of AGA may be recommended.

Alopecia areata is an idiopathic disease in which there is patchy hair loss. Many treatments for hair loss coin (less than 50% hair loss) has been proposed Including corticosteroid injections, topical 5% minoxidil, and anthralin cream or ointment on the skin without hair. Since recent studies on the role of autoantibodies and autoimmune disease in alopecia areata have raised and the drugs used in its treatment are immunomodulators, this study aimed to compare the efficiency of tacrolimus and minoxidil with minoxidil alone in the treatment of alopecia areata. This randomized, double-blind clinical trial study was done in Alzahra Hospital and Sedigheh Tahira Center of Dermatology and Leishmaniasis, affiliated to Isfahan University of Medical Sciences, from September 2012 to September 2013. In this study, 96 lesions in 54 patients with alopecia areata with various size and number of lesions were studied in two treatment groups. One group recived minoxidil 5% solution and tacrolimus 0.1% cream, and the other received minoxidil 5% solution and placebo cream. The mean lesion area at the onset of treatment, one and two months after starting the treatment, and one and three months after ending the therapy were measured compared between the groups in both sexes and various ages. After the treatment, the lesions in group minoxidil and tacrolimus increased and in the group treated with placebo cream and minoxidil solution decreased. In our study, minoxidil 5% solution alone was more effective in treatment of alopecia areata compared to combination of minoxidil 5% solution and tacrolimus 0.1% cream.

Background and Androgentic alopecia (AGA) is physiological hair loss induced by androgens in genetically predisposed persons. Different medications have been suggested to treat AGA until now but there is no certain treatment. This study aimed to compare the effect of caffeine + minoxidil topical solution 2.5% and minoxidil topical solution 2.5% in AGA treatment. In this double-blind randomized clinical trial study 60 patients were enrolled. The sampling method was simple classification and patients were divided to 2 equal groups. The first group received minoxidil topical solution 2.5% and the second group received caffeine + minoxidil topical solution 2.5%. Method of treatment was the same in both groups (one milliliter of solution was applied twice a day) and follow-up was by computation of hair numbers on alopecia area in scalp. Both groups were followed in 7 stages: at the beginning of study and the days 7, 30, 60, 90, 120, and 150. Caffeine + minoxidil topical solution 2.5% was more effective than minoxidil topical solution 2.5%. There was a significant statistical difference between the groups. This study overtly showed that the effect of caffeine + minoxidil topical solution 2.5% to treat AGA was better than minoxidil topical solution 2.5%. We suggest more studies with greater sample size and longer priod of follow-up.

Alopecia in males isn''t disease، but is a physiological process due to body hormonal changes. Now، there are several methods for prevention and theatment of Alopecia. Minoxidil (Local) and finastride (oral) are common drugs for this problem which are overthe- counter drugs. It is necessary to Know about application of this drugs during flight with regard to critical conditions in flight and easily access to this drugs. In this article، we review the usability of these drugs for air crew during flight. In the military section: In Candia air force، Pilots are restricted to fly with or as copilot while taking these drugs. These drugs may be used by aircrew other than pilot after a 7 day grounding period to ascertain in any potential side-effects. In the civil section: FAA authorizes use of topical medications that promote hair growth (Rogaine، minoxidil) for flight duty. Oral medications such as propecia (finisteride) and procaine are allowed if there are no side effects after aground test period

Backgound and One important limitation of random pattern skin flap in plastic surgery is the necrosis of distant parts of the flap resulting from ischemia. This effect cause unwanted increase in the costs and hospitalization. Previously, large number of factors has been evaluated to decrease the flap necrosis. In present study we used two drugs. Main reason was their mechanism of action that seems to be similar to preconditioning pathways. Fifty-six male rats were divided into four groups. In two groups 5% minoxidil or 5% azelaic acid were applied topically to the flap area before flap elevation. In some rats of minoxidil treated group, a non selective ATP sensitive potassium channel (KATP) blocker, glibenclamide (0.3mg/kg) was injected i.p. to evaluate the role of this channel in action. In azelaic acid treated rats, some were selected for evaluation of the role of nitric oxide and therefore L-NAME (20 mg/kg), a non-selective iNOS inhibitor, was administered. Seven days after operation, the extent of flap necrosis was calculated. Topical minoxidil or azelaic acid significantly recused necrotic area of skin flap to 42% (P<0.05) and 34% (P<0.01), respectively. Combination of minoxidil and azelaic acid was the most effictive intervantion on reducing of necrotic area to 26%. Glibenclamide abolished protective effect of minoxidil (P<0.001) and L-NAME inhibited the effect of azelaic acid on skin flap survival (P<0.05). Both L-NAME and glibenclamide completely inhibited the effect of combination topical therapy. Present study suggested the role of KATP channels on minoxidil pathway and NO on L-NAME pathway of preserving skin flap survival. It seems that there is an overlap between the two pathways; however precise mechanism remained to be determined.

Telogen effluvium is a self-limited, non-scarring disease that shows itself as a diffuse hair loss of the scalp that usually occurs 3 months after an acute illness. Theoretically, Minoxidil solution has been suggested as a treatment for this condition. In this study, we compared the efficacy of the minoxidil and an herbal drug containing urtica diocia, chamomilla, thymus vulgaris, equisetum avenues and foeniculum vulgare for treating telogen effluvium. This study was a double – blind prospective study. 24 patients with telogen effluvium were allocated randomly in two groups and were treated with minoxidil and the herbal drug. Data were analyzed statistically. The mean duration of telogen effluvium in the minoxidil group was 17 weeks and in the herbal drug group was 7 weeks. This difference was statistically significant. From this study, it is condoled that this herbal drug is effective in telogen effluvium although more studies are recommended in this field.